Were long way away from recognition yet. This is not something to buy for immediate gains.
But we are getting closer. Income, real revenues will start trickling at 2016 from diagnostics, if the pivotal goes well. It's going to be interesting to see how well the products are marketed.
One to understand SC medicine is WAY under the investing radar. It's been terrible bloodbath to be invested in most SC corps.
There are precious few clinical trials in HeSC and iPSCs, none through phase 3, by the way, I think bio time now has most of them going at phase 2.
As a wild guess, something could happen to get visibility, but probably not before 2016. Considering the level of disbelief with the tech. I don't think this is likely.
Meanwhile, the business is advancing, external funds pay for P. 2 clinical trials, the company controls the IP for 66% of the technology in the SC universe, preclinical trials are being born in multitude.
And best of all, dilution is very controlled.
spinning off the subsidiaries can create stronger company valuation wise, in fact the fact that BTX doesn't reflect 70% control in Asterias is Hugh discount. The more these things happen, the better support for PPS.
One day some efficacy news will hit and then we will have s lift off. There will be many opportunities to add.
Just make sure you have a starting position, because when risk is lower, the company might be already trading higher.
News 
Market Data 
Discover 
